Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone972-9974-1444
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees24
Next Earnings Date3/18/2019 (Estimated)
OptionableNot Optionable
CELLECT BIOTECH/S (NASDAQ:APOP) Frequently Asked Questions
What is CELLECT BIOTECH/S's stock symbol?
CELLECT BIOTECH/S trades on the NASDAQ under the ticker symbol "APOP."
How were CELLECT BIOTECH/S's earnings last quarter?
CELLECT BIOTECH/S (NASDAQ:APOP) released its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.01. View CELLECT BIOTECH/S's Earnings History.
When is CELLECT BIOTECH/S's next earnings date?
What price target have analysts set for APOP?
1 equities research analysts have issued 12 month price objectives for CELLECT BIOTECH/S's shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate CELLECT BIOTECH/S's stock price to reach $12.00 in the next year. This suggests a possible upside of 952.6% from the stock's current price. View Analyst Price Targets for CELLECT BIOTECH/S.
What is the consensus analysts' recommendation for CELLECT BIOTECH/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELLECT BIOTECH/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELLECT BIOTECH/S.
What are Wall Street analysts saying about CELLECT BIOTECH/S stock?
Here are some recent quotes from research analysts about CELLECT BIOTECH/S stock:
- 1. According to Zacks Investment Research, "Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel. " (1/3/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We value Cellect based on a discounted cash flow (DCF) approach that assigns a total value of $120M to Cellect’s platform. Our valuation translates into a price per ADS of $14.00, taking into account roughly 8.8M fully-diluted ADSs outstanding as of mid-2019." (8/29/2018)
Has CELLECT BIOTECH/S been receiving favorable news coverage?
Media stories about APOP stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CELLECT BIOTECH/S earned a news impact score of 1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of CELLECT BIOTECH/S's key competitors?
Some companies that are related to CELLECT BIOTECH/S include DarioHealth (DRIO), Neovasc (NVCN), Dynatronics (DYNT), Hancock Jaffe Laboratories (HJLI), Biostage (BSTG), Invivo Therapeutics (NVIV), Alliqua Biomedical (ALQA), Avinger (AVGR), Valeritas (VLRX), United American Healthcare (UAHC), Presbia (LENS), Atossa Genetics (ATOS), Neurometrix (NURO), Viatar CTC Solutions (VRTT) and Encision (ECIA).
What other stocks do shareholders of CELLECT BIOTECH/S own?
Who are CELLECT BIOTECH/S's key executives?
CELLECT BIOTECH/S's management team includes the folowing people:
- Mr. Kasbian Nuriel Chirich, Co-Founder & Exec. Chairman (Age 61)
- Dr. Shai Yarkoni, Co-Founder, CEO & Director (Age 61)
- Mr. Eyal Leibovitz, Chief Financial Officer (Age 58)
- Dr. Amotz Nechushtan, VP of R&D (Age 59)
- Mr. Amos Ofer, VP of Operations
Who are CELLECT BIOTECH/S's major shareholders?
CELLECT BIOTECH/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Susquehanna International Group Ltd. (0.22%).
Which institutional investors are buying CELLECT BIOTECH/S stock?
APOP stock was bought by a variety of institutional investors in the last quarter, including Susquehanna International Group Ltd..
How do I buy shares of CELLECT BIOTECH/S?
Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CELLECT BIOTECH/S's stock price today?
One share of APOP stock can currently be purchased for approximately $1.14.
How big of a company is CELLECT BIOTECH/S?
CELLECT BIOTECH/S has a market capitalization of $6.20 million. The company earns $-8,140,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. CELLECT BIOTECH/S employs 24 workers across the globe.
What is CELLECT BIOTECH/S's official website?
How can I contact CELLECT BIOTECH/S?
CELLECT BIOTECH/S's mailing address is 23 Hata'as Street, Kfar Saba L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected]
MarketBeat Community Rating for CELLECT BIOTECH/S (NASDAQ APOP)
MarketBeat's community ratings are surveys of what our community members think about CELLECT BIOTECH/S and other stocks. Vote "Outperform" if you believe APOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
